This trial is testing the safety and tolerability of M1774 when given with either Drug A or Drug B to people with metastatic or locally advanced unresectable solid tumors.
6 Primary · 6 Secondary · Reporting Duration: Baseline up to 18 months
Experimental Treatment
72 Total Participants · 2 Treatment Groups
Primary Treatment: M1774 · No Placebo Group · Phase 1
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: